"versionIdentifier","rationale","uuid:ID","instanceType","id"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","469f0b33-7dc6-4001-b1cc-5efcaa5828aa","StudyVersion","StudyVersion_1"
